Literature DB >> 28033554

Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowing effect of Si-miao-yong-an decoction: Application of LC-MS/MS method to determine 6 major bile acids in rat liver and plasma.

Ziying Liu1, Yu Zhang1, Ruowen Zhang2, Liqiang Gu1, Xiaohui Chen3.   

Abstract

Si-miao-yong-an decoction (SMYAD), a traditional Chinese medicine formula, significantly reduced plasma TC, LDL-c levels and increased HDL-c level in hyperlipidemia rats. Liver function test and tissue section examination indicated that SMYAD improved liver function and reduced fat accumulation in hyperlipidemia rat liver. A LC-MS/MS method was established and well validated to evaluate major bile acids derived from cholesterol metabolism through the classic neutral pathway and the alternative acidic pathway (cholic acid, chenodeoxycholic acid and their taurine and glycine conjugates) in liver and plasma. Increased total 6 bile acids concentrations in both liver and plasma were observed after oral administration of 12g/kg/d, 24g/kg/d and 36g/kg/d of SMYAD in a dose dependent manner which contributed to eliminate of cholesterol. Cholic acid, taurocholic acid and glycocholic acid act as the main products of bile acid classic neutral synthesis pathway and show sharp increase (p<0.01) after treatment of SMYAD at dosage of 24-36g/kg/d. For liver samples, taurocholic acid level act as the largest growth section, while in plasma samples, cholic acid act as the largest growth section after SMYAD treatment, compared with Model group. By contrast, the main products of alternative acidic pathway (chenodeoxycholic acid and its glycine and taurine conjugates) show no significant increase after treatment of SMYAD. In conclusion, the cholesterol lowing effect of SMYAD may be related with the accelerated transformation of cholesterol into bile acids through the classic neutral pathway.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bile acids; Hyperlipidemia; LC–MS/MS; Si-miao-yong-an decoction

Mesh:

Substances:

Year:  2016        PMID: 28033554     DOI: 10.1016/j.jpba.2016.12.021

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

Review 1.  Traditional Chinese medicine for lipid metabolism disorders.

Authors:  Yiping Li; Xiaolong Wang; Zhijie Shen
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

2.  Feces and liver tissue metabonomics studies on the regulatory effect of aspirin eugenol eater in hyperlipidemic rats.

Authors:  Ning Ma; Xiwang Liu; Xiaojun Kong; Shihong Li; Zenghua Jiao; Zhe Qin; Pengcheng Dong; Yajun Yang; Jianyong Li
Journal:  Lipids Health Dis       Date:  2017-12-11       Impact factor: 3.876

3.  Si-Miao-Yong-An Decoction Protects Against Cardiac Hypertrophy and Dysfunction by Inhibiting Platelet Aggregation and Activation.

Authors:  Congping Su; Qing Wang; Huimin Zhang; Wenchao Jiao; Hui Luo; Lin Li; Xiangyang Chen; Bin Liu; Xue Yu; Sen Li; Wei Wang; Shuzhen Guo
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

4.  Untargeted and Targeted Metabolomics Reveal the Underlying Mechanism of Aspirin Eugenol Ester Ameliorating Rat Hyperlipidemia via Inhibiting FXR to Induce CYP7A1.

Authors:  Lu Xiao-Rong; Ma Ning; Liu Xi-Wang; Li Shi-Hong; Qin Zhe; Bai Li-Xia; Yang Ya-Jun; Li Jian-Yong
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

5.  Therapeutic Effect and Mechanism of Si-Miao-Yong-An-Tang on Thromboangiitis Obliterans Based on the Urine Metabolomics Approach.

Authors:  Hui-Yu Li; Hui Sun; Ai-Hua Zhang; Lu-Wen He; Shi Qiu; Jun-Ru Xue; Fangfang Wu; Xi-Jun Wang
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

6.  Si-Miao-Yong-An Decoction Maintains the Cardiac Function and Protects Cardiomyocytes from Myocardial Ischemia and Reperfusion Injury.

Authors:  Wenwen Cui; Shen Xin; Lingjuan Zhu; Mingye Wang; Yuanyuan Hao; Yuqian Zhao; Yang Li; Yunlong Hou
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-26       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.